1-2 of 2
Dietmar Geissler, MD
Close
Sort by
Journal Articles

Azacitidine in Acute Myeloid Leukemia with >30% Bone Marrow Blasts and <15 G/L White Blood Cell Count: Results from the Austrian Azacitidine Registry of the AGMT Study Group Versus Randomized Controlled Phase III Clinical Trial Data

Lisa Pleyer, MD DI, Sonja Burgstaller, MD, Reinhard Stauder, MD MSc, Michael Girschikofsky, MD, Heinz Sill, MD, Konstantin Schlick, MD, Josef Thaler, MD, Britta Halter, MSc, Sigrid Machherndl-Spandl, MD, Armin Zebisch, MD, Angelika Pichler, MD, Michael Pfeilstöcker, MD, Eva-Maria Autzinger, MD, Alois Lang, MD, Klaus Geissler, MD, Daniela Voskova, MD, Dietmar Geissler, MD, Wolfgang R Sperr, MD, Sabine Hojas, MD, Inga Mandac Rogulj, MD, Johannes Andel, MD, Richard Greil, MD
Journal: Blood
Blood (2015) 126 (23): 2515.
https://doi.org/10.1182/blood.V126.23.2515.2515
Published: 2015
Journal Articles

Is It Time to Redefine Response in Elderly Patients with WHO-Acute Myeloid Leukemia (AML) Unfit for Intensive Chemotherapy?

Lisa Pleyer, MD DI, Sonja Burgstaller, MD, Reinhard Stauder, MD MSc, Michael Girschikofsky, MD, Heinz Sill, MD, Konstantin Schlick, MD, Josef Thaler, MD, Britta Halter, MSc, Sigrid Machherndl-Spandl, MD, Armin Zebisch, MD, Angelika Pichler, MD, Michael Pfeilstöcker, MD, Eva-Maria Autzinger, MD, Alois Lang, MD, Klaus Geissler, MD, Daniela Voskova, MD, Dietmar Geissler, MD, Wolfgang R Sperr, MD, Sabine Hojas, MD, Inga Mandac Rogulj, MD, Johannes Andel, MD, Richard Greil, MD
Journal: Blood
Blood (2015) 126 (23): 3742.
https://doi.org/10.1182/blood.V126.23.3742.3742
Published: 2015